NEI 01
Alternative Names: NEI-01Latest Information Update: 27 May 2022
At a glance
- Originator New Epsilon Innovation
- Class Antineoplastics; Enzymes; Recombinant proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia; Solid tumours
Most Recent Events
- 25 Apr 2022 Phase-I clinical trials in Acute myeloid leukaemia (Late-stage disease, Metastatic disease) in Hong Kong (IV) (NCT05226468)
- 25 Apr 2022 Phase-I clinical trials in Solid tumours (Second-line therapy or greater) in Hong Kong (IV) (NCT05226468)
- 09 Feb 2022 New Epsilon Innovation plans a phase I trial for Acute myeloid leukemia and Solid tumor (Late-stage disease, Monotherapy) (NCT05226468)